Company

About

Amferia

Amferia

Pepparedsleden 1, Mölndal, Vastra Gotaland County 43183, SE

Amferia AB is a Swedish company that develops and markets new medical devices with emphasis on antibacterial products. The core focus of Amferia is to develop materials that can efficiently kill bacteria when used as medical devices, for example within wound care. Amferia is a spin-off from research performed at Chalmers University of Technology. The company was founded in 2018 and the founders of Amferia are Dr. Anand Kumar Rajasekharan, Professor Martin Andersson and Dr. Saba Atefyekta.

Omnio

Omnio

Umeå, AC

Omnio AB is a biopharmaceutical company dedicated to revolutionizing the treatment of diabetic foot ulcers (DFUs) through the development of recombinant plasminogen therapeutics.

Xinnate

Xinnate

Lund, Sweden

Xinnate is a young biopharmaceutical company built on groundbreaking scientific research about innate defence and healing mechanisms – evolutionary biological systems with the purpose of keeping us healthy. One of these innate defence peptides has shown to be an effective ”natural” and unique way of preventing infection as well as reducing excessive inflammation. Xinnate specializes in the development of proprietary peptide-based drugs for prevention and treatment of inflammatory diseases and infections within the areas skin and wounds, surgical materials and and biomaterials. The company was founded in 2019 and is based on 15 years of world class research from Lund University. The first area to be addressed by Xinnate is advanced wound care, and the first product is a hydrogel, the BioC wound gel, aimed for treatment of burn wounds.